Expertise in
19
conditions

Dr. Eric M. Cheung

Oncology | Hematology
3300 East South Street, Suite 304, 
Lakewood, CA 
Accepting New Patients
Offers Telehealth
Expertise in
19
conditions
3300 East South Street, Suite 304, 
Lakewood, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Eric Cheung is an Oncologist and a Hematologist in Lakewood, California. Dr. Cheung is highly rated in 19 conditions, according to our data. His top areas of expertise are Thrombocytopenia, Febrile Neutropenia, Chronic Familial Neutropenia, and Agranulocytosis. Dr. Cheung is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in AZ
Hospital Affiliations
Memorialcare Long Beach Medical Center
Uci Health-Orange
Uci Health-Lakewood
Uci Health - Los Alamitos
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Nippon Life
  • INSURANCE PLAN
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

3300 East South Street, Suite 304, Lakewood, CA 90805

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Drug, Biological
Study Drugs: GEN-1, Carboplatin, Paclitaxel
Study Phase: Phase 1/Phase 2
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Enrollment Status: Unknown
Publish Date: March 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
Enrollment Status: Unknown
Publish Date: November 08, 2023
Intervention Type: Drug
Study Drugs: AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Carboplatin
Study Phase: Phase 3
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Enrollment Status: Terminated
Publish Date: March 23, 2022
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 2
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects With Previously Treated Hematological Cancers
A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects With Previously Treated Hematological Cancers
Enrollment Status: Terminated
Publish Date: December 10, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

10 Total Publications

Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
Journal: JAMA oncology
Published: February 10, 2022
Similar Doctors
Expertise in
7
conditions
Dr. James R. Berenson
Hematology | Oncology
Expertise in
7
conditions
Dr. James R. Berenson
Hematology | Oncology
9201 W Sunset Blvd, 
West Hollywood, CA 
 (19.8 miles away)
310-623-1222
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Berenson is a Hematologist and an Oncologist in West Hollywood, California. Dr. Berenson is highly rated in 7 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Bone Tumor, Smoldering Multiple Myeloma, Waldenstrom Macroglobulinemia, and Vertebroplasty.

Expertise in
29
conditions
Dr. Sant P. Chawla
Oncology | Hematology
Expertise in
29
conditions
Dr. Sant P. Chawla
Oncology | Hematology
2811 Wilshire Boulevard, Suite 414, 
Santa Monica, CA 
 (20.7 miles away)
310-552-9999
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sant Chawla is an Oncologist and a Hematologist in Santa Monica, California. Dr. Chawla is highly rated in 29 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Myxoid Liposarcoma. Dr. Chawla is currently accepting new patients.

Expertise in
19
conditions
Dr. Tycel J. Phillips
Hematology | Hematology Oncology | Oncology
Expertise in
19
conditions
Dr. Tycel J. Phillips
Hematology | Hematology Oncology | Oncology

City Of Hope Medical Foundation

1500 E Duarte Rd, 
Duarte, CA 
 (21.8 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tycel Phillips is a Hematologist and a Hematologist Oncology provider in Duarte, California. Dr. Phillips is highly rated in 19 conditions, according to our data. His top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Follicular Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cheung's expertise for a condition
ConditionClose
      View All 19 Advanced Conditions
      View All 118 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile